Innovative Cancer Marker wins Queen's Award
Binding Site has been named as a winner of The Queen's Award for Enterprise in the category Innovation 2007.
The award has been granted in recognition of the development of Freelite™, a new diagnostic assay for the diagnosis and monitoring of multiple myeloma, a type of Bone Marrow cancer.
Launched in 2000 the Freelite assay is used in hospital laboratories worldwide to help diagnose this cancer and to monitor the effectiveness of treatment in patients receiving chemotherapy. Previously used laboratory diagnostic techniques were not always as sensitive as the Freelite assay which allows doctors to use a simple blood test to monitor their patients. In rare forms of the disease, monitoring with Freelite is the only way of assessing whether a patient is responding to therapy or whether the therapy needs to be changed to better treat the patient. In this group of patients the Freelite assay has revolutionised the way doctors can select the appropriate treatment for each individual patient.
Presentation Ceremony
The Queen's Award for Enterprise 2007 Innovation was presented to Binding Site by Sir Adrian Cadbury, deputy Lord Lieutenant of Warwickshire, during an afternoon of celebration at the company's headquarters in Birmingham, UK. The ceremony, held on 24th October 2007, was also attended by the Lord Mayor and Lady Mayoress of Birmingham, the Chancellor of the University of Birmingham, Sir Dominic Cadbury, plus colleagues from finance, medicine and business.
.jpg)